tirzepatide being discontinued Compounded GLP-1 - Semaglutide & FDA says tirzepatide shortage is

Our dedication to safe, effective weight loss and individualized care forms the bedrock of our approach

This makes shakes easier to sip slowly and easier to tolerate from start to finish

In Phase 3 TRIUMPH-1 (May 21, 2026), the 12 mg arm averaged 28.3% weight loss at 80 weeks, and a higher-BMI subgroup reached 30.3% at 104 weeks

Heres what to expect: Common side effects: Nausea (especially in the first few weeks) Vomiting Diarrhea Constipation Abdominal pain Bloating These effects typically improve over time as your body adjusts to the medication

Common experiences include mild nausea, digestive changes, or fatigue, which often ease within weeks

REMS is uniform across all US territory and cannot vary in individual states